Biotech Breakouts & Bitcoin Bets

September 12, 2025

DENVER, Colo., Sep 12, 2025 (247marketnews.com)-  Wall Street is waking up to a red-hot biotech blitz this morning, here’s your top-of-the-morning rundown:

Yesterday’s market star, LIXTE (NASDAQ:LIXT), is again in the spotlight after blasting through its 52-week high on solid volume. The clinical-stage oncology biotech stunned traders and investors alike with a strategic treasury allocation to cryptocurrency, revealing it now holds 10.5 Bitcoin and 300 Ethereum, representing 43.6% of its treasury, with plans to go as high as 50%.

This bold move triggered a wave of retail momentum, crypto-aligned speculation, and a potential short squeeze in motion. Short interest remains notably elevated, and with Phase 2 trial news pending, bulls are betting this is more than just a one-day pop. Look for extended moves in after-hours, especially if Bitcoin or Ethereum spike or the company follows up with another press release.

Cocrystal Pharma (NASDAQ:COCP) impressed at the 9th International Calicivirus Conference with its podium presentation of CDI-988, its first-in-class oral antiviral for norovirus infection. President and Co-CEO Dr. Sam Lee highlighted Phase 1 data, a strong safety profile, and FDA IND clearance for a human challenge trial expected to begin by year-end.

CDI-988 was developed using Cocrystal’s proprietary structure-based drug discovery platform and targets a broad range of norovirus genogroups, notably GII.4 and GII.17, which are responsible for most outbreaks. With no current approved oral treatment for norovirus, COCP could be positioned for a first-mover advantage in this unmet market.

Polyrizon (NASDAQ:PLRZ) reported encouraging preclinical data for PL-14, its intranasal hydrogel-based allergy blocker, showing over 60% targeted deposition in the nasal vestibule, a critical site for airborne allergen interception. The study, done in partnership with Italy’s University of Parma, reinforces the company’s “capture & contain” approach for treating allergic rhinitis.

The allergy blocker market is expected to grow to $0.21 billion by 2033 and PLRZ is angling for a first-line, non-pharmaceutical treatment niche. The formulation’s favorable sprayability and practical self-administration profile further support its consumer viability.

HCW Biologics (NASDAQ:HCWB) is riding high after reporting strong non-human primate safety data for its second-generation T-cell engagers (TCEs), targeting solid tumors like pancreatic cancer and glioblastoma. The company’s proprietary TRBC platform aims to solve the efficacy, tolerability, and manufacturability challenges faced by first-gen TCEs.

CEO Dr. Hing C. Wong confirmed the company is now seeking corporate partners to advance clinical development. With 100% survival in preclinical tumor-bearing mice and no signs of cytokine storm in primates, HCWB’s program may draw attention in upcoming biopharma deal-making rounds.

Glucotrack (NASDAQ:GCTK) a medical tech firm focused on diabetes management, is prepping for a key visibility moment at the Q3 Virtual Investor Summit (Sep 16–17). No clinical data yet, but investor exposure could drive sentiment ahead of any future announcements.

Hong Kong-based Majestic Ideal Holdings (NASDAQ:MJID) received shareholder approval to officially change its name to “Ping An Biomedical Co., Ltd.”, a move the board says better reflects its strategic focus on healthcare innovation. While not a price-moving event on its own, the rebrand could precede shifts in business direction, potential partnerships, or M&A activity.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by Microcap Advisory for providing ongoing LIXT and XHLD market outreach and other services. Please review our Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT and 247marketnews.com disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (LIXT, COCP, PLRZ, HCWB, GCTK, MJID)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.